5+ Views

How COVID-19 Impacted on Emergency Medical Transportation in Healthcare Industry ?

The global outbreak of SARS-CoV-2 virus has led to a major public health problem due to the emergence of COVID-19 pandemic. The impact of pandemic on healthcare services has been straining and governments as well as players in healthcare industry are monitoring demand types and volumes to anticipate future resource needs. The pandemic has led to a rise in demand for emergency transportation for medical services, however, in numerous cases the demand has been affected due to public apprehension for fear of infection regarding involvement with the health system.
The demand for emergency transportation is especially driven by customized transport vehicles offering emergency care services to COVID-19 patients such as inclusion of emergency transport ventilators. Several notable emergency transport manufacturers and providers have integrated advanced technologies and equipment in order to cope with the mounting emergency services demand. As a response to COVID-19, numerous players in the market are getting involved in strategic agreements and collaborations with companies in all parts of the value chain.
For instance,
· BS6-compliant Supro developed by Mahindra is equipped with beacon light, 75 percent frosted windows, and AIS 125- certified retro-reflective decals. Similarly, many companies are involved in introducing enhanced products along with simultaneously boosting production to capture larger market share.
COVID-19 pandemic has significantly driven the market for emergency medical transport across the world. The persistence of the COVID-19 for a prolonged period has driven the demand for emergency medical transportation.
Throughout the pandemic, the use of ambulances has risen. The demand for EMS (emergency medical service) such as medical transport for "time-sensitive diseases" such as heart conditions, strokes, and acute abdominal diseases among others has also increased. Increasing number of COVID-19 patients across globe has boosted the demand for emergency medical transportation and is anticipated to drive the market growth during the forecast period.
Increasing patient suffering from chronic diseases is a key factor driving the demand for emergency medical transportation services in the globe market, throughout the analysis period. Additionally, the growth in road accidents is also creating a need for ambulance or emergency services.
Emergency medical transportation (EMS) and acute medical service that insurance companies include in plans are affected due to the pandemic. For senior population the acute medical service offered by EMS transportation is available for hospitalization. These factors have increased the cost of ambulatory services. COVID-19 has impacted the emergency medical services due to surge in prices for emergency medical services.
EMS transportation is incentivized by major insurances across globe. However, the cost of emergency medical transportation has increased during the pandemic due to requirement of additional personal protective equipment, staff shortages, increasing cleaning and sanitization cost, and decreased reimbursement.
The sudden rise of the COVID-19 pandemic enforced an optimistic impact on the global emergency medical transportation market growth in 2020. Rising demand for emergency medical transport for offering emergency care services for COVID-19 patients during the pandemic is driving the growth of the market. During COVID-19 pandemic, key ambulance service providers and equipment & vehicle manufacturers have incorporated various advanced technologies as well as boosted the production to deal with the increasing demand for emergency medical transportation and equipment.
The unprecedented outbreak of COVID-19 has positively affected the demand for emergency medical transportation. In order to prevent the outbreak, NGOs, charity institutions, semi-governmental & governmental bodies are all focusing on deployment of emergency transportation. There are numerous startups that emerged to cope up with the high demand for emergency transportation.
For instance,
· A startup called eSahai based in Hyderabad experienced heightened operations amid the pandemic outbreak with requests via mobile apps and call centers. The emerging services are especially in high demand for worst affected countries that lack necessary healthcare related resources.
The emergency services had an asset utilization issue where occupancy rate was very low. Most hospital emergency transportations are often stretched thin while private transports are under-utilized due to their lack of standards. The private transport owners’ lack of medical know-how has affected the quality of transport provided. The precaution and quality are especially relevant in cases of COVID-19 patients where the risk of infection is very high due to the contagious nature of the virus. The lower quality of the transportations has led to an increased and enhanced supply from budding startups and service businesses.
For instance,
· StanPlus, an emergency transportation service served 10 times demand in 2021, where over 70% of the requests were COVID-19.
In response to the surge in demand for this equipment, vendors are raising funds and developing platforms and tools that meet the needs for COVID-19 surveillance and treatment. For instance,
· The American Ambulance Association recently begged the Department of Health and Human Services for USD 2.6 billion in emergency funding.
Emergency medical transportation such as ambulance providers are hostile to meet rising demand even though the cost has increased due to personal protective equipment, staff shortages, as well as decreased reimbursement.
The government imposed total lockdown which led to supply chain disruptions. Consequently, the supply chain came to standstill due to the closure of borders. Even though the demand for ambulance and equipment use in emergency ambulance was high, the availability was affected due to disruptions in the supply chain, trade, and travel restrictions. Supply of raw material was also affected, due to which the production was restricted. Bottlenecks in the supply were foreseen due to limited production. Still, some companies managed to overcome the challenges and saw high growth.
Government has also taken initiatives to regularize the supply of equipment uses in ambulance and emergency medical vehicles. So there is limited effect of COVID-19 on supply chain on the emergency medical transportation market.
The supply chain and logistic disruption of equipment use in emergency medical transportation and disruption in ambulance manufacturing has hampered the market for initial phase of pandemic however this equipment are considered under essential medical devices, due to which it’s supply is regularized during the pandemic situation.
As the reality of COVID-19 dawned upon the world, the service provider, manufacturers and production units of companies involved in emergency medical transportation formed strategies to deal with the limitation that occurred due to coronavirus and keep their business running.
For instance,
All providers had developed special procedures and safety instructions in preparation for COVID-19. Ground ambulance transport was the preferred mode of emergency medical transport in primary missions, whereas air ambulance transport was preferred for interfaculty emergency medical transport.
Several manufacturers are following similar strategic patterns and procedures to gain an edge on decisions taken regarding production as well as sales.
Several manufacturers of emergency medical transportation market also coming forward to help each other in terms of finance as well as other market parameters to not only save the market scenario but to save themselves from the brutal grasp of the pandemic.
Pandemic has taken a toll on every aspect of life, including the global economy. With the significant downfalls in many sectors, a collaborative effort of government, industry players, and consumers can win the fight against COVID-19.
It still continues to inflict the world with appalling economic and social dilemmas, capable enough to leave severe backlash on the economy for the next several years. The first wave had already inflicted severe blows to the population as well as the economy. The currently experiencing second wave is expected to be more disastrous not only to the masses but also to food and beverages markets.
Moreover, key companies and government bodies are exclusively concentrating on how they can make the effective and best contribution to control the spread of the virus and save lives. Key companies are dealing with the suddenly increasing demand for emergency medical transportation services by implementing various strategies to overcome current problem and to fulfil the rising demand for emergency medical transportation.
COVID-19 has impacted each sector with no exception. The emergency medical transportation market has been affected the same. With rising number of COVID-19 patients led to increased demand for emergency medical transportation. Global emergency medical transportation market is experiencing a boost due to the ongoing COVID-19 Pandemic due to the above given factors. Global emergency medical transportation market is experiencing a boost due to the ongoing COVID-19 pandemic.
Cards you may also be interested in
Significant Impact of COVID-19 on Bioresorbable Scaffolds in Healthcare Industry
COVID-19 Impact on Bioresorbable Scaffolds in Healthcare Industry Coronavirus disease 2019 (COVID-19), also known as SARS-CoV-2 or 2019-nCoV, is a human infectious disease caused by the coronavirus that causes severe acute respiratory syndrome. COVID-19 was declared a pandemic by the world health organization due to the rapid rise in human infection rates. This pandemic has influenced the whole planet with its major impacts on the economy and businesses across the globe. The virus has spread across all regions ranging from North America, Europe, Asia-Pacific, Middle East, and Africa up to South America. After the pandemic declaration, various countries such as Russia, Europe, and Asia announced the complete lockdown to decrease its spread. During this pandemic of COVID-19 the rising prevalence of cardiovascular diseases and accompanied surgery adoptions is accelerating the market growth. Amid this pandemic the demand for bioresorbable scaffolds is increasing as they provide complete resorption and temporal mechanical support for patients. According, to the situation report of 20 July 2021, by WHO, 190 million cases of coronavirus patients have been reported globally, and 4.08 million patients are dead due to the coronavirus. America is leading in cumulative cases with a record of 74 million and 1.9 million death rates. More than 4.21 billion doses of Covid-19 vaccines have been administered in around 180 countries. The outbreak of COVID-19 is having a huge impact on the healthcare and supply chain of various medical products, including Bioresorbable scaffolds. Bioresorbable scaffolds are widely used as potential solution for coronary artery diseases. These scaffolds prevent the adverse reactions caused by permanent metallic devices during percutaneous coronary intervention, which is safe, effective, and timely preferred treatment for coronary artery diseases. Usually, permanent metallic devices prevent the natural process of vessel restoration and remodeling, which makes future revascularization more complicated. Hence, bioresorbable scaffolds are preferred to prevent these complications since they can provide temporary support and then degrade for natural restoration to take over in vessels. Price Impact The COVID 19 had a devastating impact on the global economy. The several establishments had to remain shut while others scaled down the operations or put hold on expansion plans as they tried to survive the unprecedented crisis. However, the rising cardiovascular cases increased the demand for vascular restoration surgeries. In spite of lockdowns and supply disruption crisis during this pandemic, the companies managed and are still managing online sales for many medical scaffolds and their products. They are also maintaining fair prices due to the high demand of these products in the market, but due to the supply chain disruption, the prices have raised slightly. For instance, · As per a survey done in five U.S Hospitals, the price of scaffold Bioresorbable stents was estimated to be 1, 250 USD per stent. And Abbott sells Bioresorbable Vascular Scaffolds BVS for USD 1,743 and Everolimus-Eluting Bioresorbable Scaffolds EES for USD 1,638 The COVID-19 impact has not affected the price of scaffolds and based products at a high level because of advanced online sales and innovative delivery options available with utmost safety concerns to major coronary surgeries conducted in hospitals. Impact on Demand The COVID-19 pandemic has impacted the bioresorbable scaffolds market from its niche pedestal to the mainstream sector. Even before the pandemic, the bioresorbable scaffolds were in high demand due to rising chronic coronary artery diseases and advanced methods for treatments of these diseases like vascular restorations globally. For instance, · As per the American College of Cardiology in 2018, the use of stent scaffolds in cardio surgeries started back in mid-1980s. But due to many adverse reactions of metallic scaffolds, which resist the natural vascularization process in arteries, researchers showed wide interest in bioresorbable scaffolds The rising transmission rate of coronavirus in the recent scenario has made high hospital admissions for various chronic diseases and respective demand for surgical scaffolds. The most widely used bioresorbable scaffold is ‘Absorb BVS’, made of PLLA scaffold coated with Everolimus-Eluting PDLLA. This is 150 micron size which can reabsorb for 4 years altogether. Coronary artery disease is major heart disease that affects both men and women irrespective of age globally. For instance, · According to the Center for Disease Control CDC; coronary heart disease has been estimated to be around 18.2 million in adults aged 20 and above. In 2017, the mortality rate was 365,914 due to coronary artery diseases. About 2 out of 10 individuals are killed due to the disorder in adults who are less than 65 years of age. This increases the demand for surgeries and vascular restoration for the timely treatment of most coronary disease conditions. Several companies operating in other domains are eager to enter, and some have already entered the landscape of bioresorbable scaffold market to increase their revenue by meeting the emergent need of various hospitals for coronary artery surgeries. The demand is further rising in local clinics and small laboratories due to high awareness of the disease and their advancements in surgical procedures. Impact on Supply Chain The COVID-19 has created a great impact on the supply chain of bioresorbable scaffolds. The sudden attack of COVID-19 and its subsequent impact on restrictions on trade and movement of goods has resulted in a shutdown of vast countries globally, resulting in disrupted supply chains due to limited raw materials and workforce, and slow down or stopping of manufacturing. Moreover, several manufacturing companies are retooling priority manufacturing to produce other essential medical supplies and equipment such as ventilators. But considering the need of these scaffolds in coronary heart diseases surgery and an increase in order from the consumers, the government allows the movements of transport vehicles to import and export the medical and surgical scaffold or implants products which is highly required by hospitals and other healthcare sectors. Additionally, the manufacturers are also taking crucial steps to ensure the availability of raw materials and look into the quality of products. Manufacturers need to take necessary steps about production processes, shifting to other facilities if required, changes in quality assurance, costs and procedures related to screening of workforce and offering care if needed, changes in working hours, and others in order to maintain their supply chain. To minimize supply chain crises, the government has been firmly monitoring the supply chain to assume that the COVID-19 outbreak may adversely impact the supply chain of medical products, including shortages of bioresorbable scaffolds for various surgical purposes to coronary healthcare sectors in countries globally or potential disruptions in supply chains. To manage such a crucial situation, many organizations are looking forward to improving and diversifying the supply chain model in all aspects. The resulting COVID-19 pandemic has shown the various ways for supply chain management, which may be effective by innovative solutions initiated by market players. STRATEGIC DECISIONS OF GOVERNMENT AND MANUFACTURERS The key players engaged in the global bioresorbable scaffolds market are making improvements to keep the speed during COVID-19. They are cautiously taking every single step so the development can be expanded on a consistent schedule for the market. Organizations working in the bioresorbable scaffolds market embrace a few systems, including joint effort, arrangements, association, and market development to improve their business. For instance, · On September 3, 2020, Abbott, the primary key player in the bioresorbable scaffolds market, announced that they had initiated a LIFE-BTK clinical trial for evaluating the effectiveness of Esprit BTK Everolimus Eluting Resorbable Scaffold, which was used for people battling with late stages of peripheral artery disease (PAD). Even during the pandemic, the company is making many initiatives to resume their products manufacturing and trial over the market to strengthen their position. Conclusion The impact of the novel COVID-19 virus is expected to leave a long-lasting impact on each healthcare sector. The virus poses a risk to human life and has caused economic distress and severe emotional strain. It produced a ripple effect that gave rise to a new collection of requirements and needs that were not much needed earlier. The most essential one being the bioresorbable scaffolds and medicinal products, which are highly needed in hospitals, clinics, laboratories due to rising chronic cardiovascular and coronary artery diseases and surgical emergence globally. It is estimated that the COVID-19 pandemic has a negative impact on the market's growth due to the surgery cases of coronary diseases being halted unless emergence. The current priority in most hospitals is given for COVID-19 treatments as the surge of COVID-19 cases keeps increasing each day. Moreover, many International governments, including U.S, Europe and Asia’s healthcare organizations, have supported the supply of these scaffold products due to high priority in this crucial health crisis period. Many government bodies and significant market players are closely associated with patients and pharma industries for safe packaging of products considering contagious nature of the virus and improvement of future economics.
How COVID-19 Impacted on Niemann-Pick Disease in Healthcare Industry ?
COVID-19 Impact on Niemann-Pick Disease in Healthcare Industry OVERVIEW A novel coronavirus, SARS-CoV-2, appeared in December 2019 in Wuhan, China, spreading much faster than its predecessors and has already infected millions of patients worldwide as of April 19, 2020. As the scope of the current COVID-19 outbreak has reached the proportion of pandemics, significant international efforts in public health are underway to control the epidemic. The covid-19 pandemic majorly impacted the rare diseases patients because, during the pandemic, the need to provide high-level care for a large number of patients with COVID-19 has affected resourcing and limited the routine maintenance of all other conditions. The impact of health emergencies particularly faced by the rare disease communities, organizations, clinics, and other healthcare providers. The health economic challenges faced by patients and their families, institutions, research organizations, and healthcare providers during the pandemic outbreak have demonstrated the importance of ensuring continuity of care in the management of rare diseases, including adequate diagnostics and monitoring protocols, and highlighted the need for a structured emergency strategy. Niemann-Pick disease is a rare, inherited disease that affects majorly body's ability to metabolize fats such as cholesterol and lipids within the cells. Over time, these cells got malfunctioned and died. The disease can affects the brain, spleen, nerves and, if get severe, may affect lungs, bone marrow, and other organs. The disease can occur at any age but majorly affects children. There is no known cure for the disease, and sometimes it may be fatal for children, the only treatment is focused on helping people live with their symptoms. IMPACT ON PRICE Various market players are facing a large number of challenges due to the coming of the novel coronavirus and different strains; one such issue is the uncertainty surrounding the impact of covid-19 on off label drugs demands. Due to the increased coronavirus cases and continuous lockdown, the costs of the drugs and their APIs increase automatically. On the one side, it will increase the revenue of the companies, but a patient may resist buying the products, which ultimately increases the stress level on the patients. Moreover, Due to the pandemic, there is the delay associated with various types of limitations faced by the manufacturers to fulfill the end product order, which has resulted in the less availability of medical devices in the market and due to which the cost of available devices has increased with the several factors. Also, due to the Coronavirus disease (COVID-19) pandemic outbreak, manufacturers are forced to find new contract manufacturers and suppliers for more manufacturing activities to different or unique facilities location that are less impacted by the outbreak. The impact of Covid-19 has created huge price impact on the government as well as on patient families that they have to buy the drugs on higher rate as compared to the average rate. IMPACT ON DEMAND The Coronavirus zone is the result of various markets around the world. This is the cause of the widespread closures and isolation that are affecting world economic activity. As the cases increases in the month of April 2020, the sudden surge in demand has seen, and drugs and medical devices went out of stock. Moreover, the decrease in the revenue of the key market players depicted in their quarterly results, such as Medtronic, among others, gave the evidence of decline in the demand for medical devices due to the emergence of the COVID-19 pandemic. For instance, · Medtronic reported a decline of 1% in its brain therapies net sales of the financial results of 2020 as compared to 2019. The reduction was primarily motivated by the detrimental effects of the COVID-19 pandemic and the subsequent deferral to companies of medical procedures. · Impact on rare disease organization also faced significant fundraising income loss, this consequential income loss may leads to loss of various people jobs associated with the organizations. The cutting or income loss leads to the reducing staff, canceling offices leases, and delay or cutting office programs. The impact of covid-19 majorly impacted the organizations if the revenues loss projections do not change, this will leads to temporarily or permanently shut down of small and middle foundations and organizations. IMPACT ON SUPPLY As the epidemic intensifies, supply chains can be at significant risk due to over-located locations that can potentially be disrupted. The supply chain of drugs, devices, and services has been disrupted. The spread of COVID-19 makes it difficult for governments to use these drugs; the availability of these systems faces constant challenges due to their components of use and limited initial needs. Moreover, as there is no cure for the disease, only physical activities/therapies may suppress the symptoms also affected by pandemics. According to the NORD (National Organization for Rare Disorders), in the U.S. stated that 74% of the population have had canceled medical appointments due to Covid-19 pandemic, 69% of population concerned about their medication and medical supplies. For instance, • In June, ResMed stated that, due to the Covid-19 pandemic company sleep apnea business segment adversely affected including sleep clinics, physician practices, HME suppliers. As new patients are prescribed sleep apnea devices such as PAP, CPAP devices for the treatment through hospitals that are directing their resources to critical care, including COVID-19 treatment. The covid 19 impacts may continue to decrease demand for the sleep apnea devices sale STRATEGIC DECISIONS OF GOVERNMENT AND MANUFACTURERS As such, market participants are involved in the production of drugs, expanding their business through a variety of programs, including collaboration, contracts, and pipeline development, collaboration, and market expansion. It is expected that the strategic decisions of these companies will provide significant opportunities for market participants operating in the Niemann-Pick Disease market. For instance, · In July 2020, Abbott announced that it had received FDA approval for the use of the Patient Controller App on compatible personal Apple smartphone devices. The approval will allow the patient living with neurological conditions to manage their therapy directly from personal smartphone. · In May 2020, Philips, a global leader in health technology, joined forces with the American Telemedicine Association (ATA) to help further the adoption of telehealth across the industry, demonstrating its commitment to connecting care across acute, post-acute, and home care settings. The continued collaboration spotlights telehealth's growing adoption and momentum amidst COVID-19 and the need to convey the exponential shift to telehealth capabilities. · In U.S., NIH supports the research survey of “CURE EPILEPSY ORGANIZATION” to examine the impact of Covid-19 on Rare Disease Community. The survey includes more than 200 rare diseases including the brain, immune system disorders, heart, lungs, brain development diseases, and more. CONCLUSION As this pandemic situation has resulted in many restrictions in different places around the world, still the market players of dealing in rare diseases therapy and services were able to manage their service stock. Different companies dealing in metabolic diseases therapy services were finding out their own way to deal with this pandemic situation. The government and companies around the globe are working together and have issued advice for those undergoing therapies centers during these unprecedented times during COVID 19 lockdown around the world. The supply chain was destroyed, but several steps were taken by the government and companies, which will help them, get their needed output for therapy service. By increasing the material price, the companies can maintain their overall revenue. Thus, different foundations, organizations,, and services center markets are finding ways to deal with this pandemic situation. Figure 1: Relationship between Coronavirus and Lysosome storage diseases : Coronavirus Cell Entry Occurs through the Endo-/Lysosomal Pathway
Tummy Tuck And Liposuction In A Nutshell
Abdominoplasty, more commonly referred to as a tummy tuck, is a surgical procedure that flattens the abdomen by removing excess fat and tightening the skin around the stomach. If sit-ups and abdominal exercises are not yielding results, you should consider abdominoplasty. Skin tightening and fat removal will be performed during this procedure to reduce the size of your tummy and abdomen. Before undergoing this procedure, you should consult with the best plastic surgeon. This surgery may be mild to severe, depending on the size of your abdomen and the desired shape. Bear in mind that this is not a replacement for weight loss. The ideal candidate for tummy tuck surgery. As with any other surgery, a tummy tuck is only appropriate for physically fit men and women. Women, in particular, have loose skin around the abdomen area following multiple pregnancies. It is a remarkable procedure for men and women who were obese and remain so. They can combine liposuction and a tummy tuck for optimal results. What are the differences between a tummy tuck and liposuction? Liposuction is the way to go if you want to remove a small amount of fat from your hips, arms, or tummy. If too much fat is removed, the skin around the affected area may droop. If you're trying to lose weight, avoid liposuction or abdominoplasty surgery. However, if you have lost a significant amount of weight and are left with excess fat and tissue, an abdominoplasty can be used to remove the excess fat and tissue. Additionally, it is beneficial to tighten the skin around the abdomen. If your BMI is greater than 30 or you anticipate becoming pregnant in the near future, a tummy tuck may be right for you. It is advantageous if you have cardiovascular disease. Preparation for abdominoplasty. When you schedule a consultation with a cosmetic surgeon for Tummy tuck surgery, you will discuss your desired outcome. The Surgeon may present you with a number of abdominoplasty options. Tummy tuck (complete). As the term implies, the surgeon will make a hip-to-hip incision and remodel it by removing excess fat and tightening the skin. The doctor will insert drainage tubes beneath your skin for a few days during this procedure. Tummy tuck (partial). Depending on your situation, the doctor may elect not to relocate the belly button and instead make an incision below the belly button on your abdomen. This procedure may take between two and three hours. Time for recuperation. When you regain consciousness, you will notice an incision around your abdomen that has been bandaged. To avoid bacterial infection, this surgical dressing must be changed multiple times during the recovery period. Within a day or two, you will be able to walk with assistance. This will also aid in your healing process. Additionally, the doctor will prescribe pain relievers and antibiotics to alleviate discomfort and prevent infection. Recuperation is expected to take between 2-4 weeks.
Amniotic Products Market - Anticipated To Witness High Growth In The Near Future
According to the new market research report “Amniotic Products Market by Type (Amniotic Membranes (Cryopreserved Amniotic Membranes, Dehydrated Amniotic Membranes), Amniotic Suspensions), Application (Wound Care, Ophthalmology, Orthopedics), End User (Hospitals, ASCs) – Global Forecast to 2026″, published by MarketsandMarkets™, the global amniotic membranes market is projected to USD 1.0 billion by 2026 from USD 0.7 billion in 2021, at a CAGR of 8.2% during the forecast period. Browse in-depth TOC on”Amniotic Products Market” 191 – Tables 37 – Figures 205 – Pages Download PDF Brochure: The growth in amniotic membranes market can be attributed to the growth in the target patient population, rising incidence of burn injuries, awareness programs for wound care treatment and management, rising venture capital investments and government funding, increasing number of traumatic wounds, growing number of amniotic membrane transplantations, and the increasing number of ophthalmology, cosmetic, and orthopedic surgeries. Emerging economies, implementation of the 21st-century cures act, and increasing demand for stem cell research and regenerative medicine are expected to offer strong growth opportunities for players in the market. In contrast, the complications and limitation associated with the use of amniotv membrane may challenge market growth to a certain extent. The amniotic products market is segmented based on type, application, end user, and region. The amniotic membrane segment is expected to grow at the highest CAGR during the forecast period and iodinated contrast media accounted for the largest share in 2020. Based on type, the amniotic products market is segmented into amniotic membranes and amniotic suspensions. Amniotic membrane account for the largest share of the market. The large share of this segment can be attributed to the increased use in a number of procedures. Moreover, amniotic membranes are more effective than amniotic suspensions. Request Sample Pages: North America was the largest regional market for the amniotic products market in 2020 The amniotic membranes market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America and the Middle East & Africa (MEA). North America was the largest regional market for market in 2020. North America is expected to hold the largest market share and highest market growth during the forecast period. The large share of the North American market can be attributed to high prevalence of target diseases, increasing geriatric population, rising awareness about advanced treatment options, and the strong presence of key market players in the region. The global amniotic products market is consolidated. The prominent players operating in this market include MiMedx (US), Smith & Nephew (UK), Organogenesis Inc. (US), Integra LifeSciences (US), Stryker (US), Applied Biologics (US), Celularity, Inc. (US), Katena Products, Inc. (US), Lucina Biosciences (US), Skye Biologics Holdings, LLC (US), Surgenex (US), TissueTech, Inc. (US), and Ventris Medical, LLC (US). Speak to Analyst:
CBD for Sleep, CBD Benefits, Side Effects, and Treatment
People have long used the cannabis plant for medicinal and recreational purposes. Compounds called cannabinoids in the plant are responsible for the effects on the brain, and the two most abundant of these are tetrahydrocannabinol (THC) and cannabidiol (CBD). People use CBD for a variety of reasons, including reducing seizures, anxiety, and pain. Some studies have demonstrated that CBD may also be a sleep aid. In this article, we look at whether it works and any associated risks. What the research says In the last decade, growing public interest in the benefits of marijuana, and CBD in particular, has encouraged researchers to study its effects. Early studies indicate that high dosages of CBD may support sleep. One investigation found that, compared with a placebo, a CBD dosage of 160 milligrams (mg) increased sleep duration. The researchers also concluded that the placebo, 5 mg of the insomnia drug nitrazepam, and 40, 80, and 160 mg of CBD helped the participants fall asleep. The stress hormone levels of cortisol are typically peak in the morning, but people with insomnia may have high cortisol levels at night. Independent of insomnia, having high cortisol levels at night is associated with an increased nighttime awakening. In one study on the effects of CBD, researchers found that cortisol levels decreased more significantly when participants took 300 or 600 mg of CBD oil. These results suggest that CBD affects the release of cortisol, possibly acting as a sedative. A more recent analysis of CBD and sleep recruited 103 participants who had anxiety or poor sleep. The researchers studied the effects of CBD combined with those of other prescribed medications. The CBD dosages ranged from 25–175 mg. The researchers found that 25 mg was the most effective dosage for anxiety and that addressing troubled sleep required higher dosages. During the 3-month study, the investigators followed up with the participants monthly. At the first follow-up, 66.7% reported an improvement in sleep, but 25% had worsened sleep. 56.1% of the participants reported improved sleep at the second, but 26.8% had worsened sleep. The researchers conclude that although CBD might help people sleep in the short term, the effects may not be sustained. Side effects and other risks of CBD Overall, the available evidence suggests that CBD is well-tolerated. Some people report fatigue and mental sedation with CBD use, but researchers believe this may be related to the dosage. Taking 10–400 mg of CBD per day for an extended period and by different routes did not have a toxic effect on participants in a large retrospective study. Even dosages of up to 1,500 mg per day were well-tolerated, other researchers report. However, determining whether there are long-term risks of CBD use will require further studies. So far, no reports of lethal CBD overdoses exist. Some researchers may be concerned about CBD abuse, but information on significant complications is limited. One study indicates that dosages of 400–700 mg of CBD, which is considered high, can aggravate cognitive deficits in people with schizophrenia. Combining CBD and THC may, however, improve cognition. Researchers do report that CBD may cause other adverse effects, including: alterations of cell viability in studies conducted in cell cultures decreased fertilization capacity inhibition of drug metabolism in the liver reduced activity of P-glycoprotein and other drug transporters If these effects on drug metabolism and transportation are confirmed, it would indicate that CBD interferes with other medications. Overall, more research is necessary. Still, it is suitable for anyone who wants to use CBD to speak with a healthcare provider first. Check out the best CBD for sleep at Sweet Dream Beauty website.
True Opinions About Best Pain Patch
Many people have a a lot of mishaps, traumas, and therefore serious complications that lead to persistent torment. Many individuals use medications in lessen aches, as well as utilize aerosols then natural to avoid inflammation and pain effortlessly. Dependant on web sites state, some suppose that they often acquire getting rid of distress via a certain amount of anesthetics, even so it may well be injurious to consider painkillers repeatedly. You will find some advice that may possibly deliver prompt healing however are accessible for a short lived job, what this means is easier confer with clinical professionals to remove the anguish. Folks likewise use advanced products and services, for example pain patches to minimize problems correct. The employment of the particular pain patch has grown on account that pain relief patches have better outcomes in a few minutes. People today can make use of a fabulous pain relief patch to bring down nck physical pain, knee serious pain, sciatica, as well as major problem minus the challenge. Many of us constantly opt for pain patches once they get physical pain in his or her parts of the body. With the use of another pain relief patch, individuals feel much better and enquire of do away with abnormal hurting within seconds. This is a is really complete of various types of pain patches, for example ,, adhesive, cream pain patches, heat patches, electrotherapy patches, and so much more. The models of pain patches can bring much better brings about all people. Men and woman that start using models of updates will have free of pains competently. A certain amount of pain patches are produced that includes experienced technological innovation, whilst some consists of very successful things to calm the tissues and provides ease. Everyone has started to many options to get pain patches, however render importance at the best pain patches. Deciding on the best pain patch isn’t less of a challenge if anyone is simply every pain patch professional intentions to have better improvements. Add-ons ., serious in taking up people young and old will be able to go to this page and / or maybe stop by the proper a website to discover more about the best pain relief patches. click here As much as your best pain relief patch is worried, individuals can find the top pain patches without problem, for example ,, Luminas, FeelZing, Stamina Pro, Melzu, sometimes more. These will be the top pain relief patches people may very well effortlessly use to take out pain sensation fairly quickly. Reported by sites study, those find greatest results with these pain patches. A lot of folks are choosing the actual above-mentioned pain patches to make sure you offset her or his distress. A number specialists claimed that pain patches are only for brief alleviation, which means families needs to seek advice from her or his researchers principal to generate prolonged therapy. Trying pain relief patches typical intended for short term therapy should be uncontrollable if you are. The very above-mentioned pain patches have the capability to settle-back muscular areas, shrink pain, and in addition terminate irritability very quickly. Every one of those pain patches is available to a realistic rate. People that have wants comprehend these best pain patch reviews along with other factors really feels liberal to go to see this incredible website.
Lose weight Quickly: Just how To Make It Happen Safely and securely
Power training and bodyweight coaching exercise help you stay lean because they build muscle as well as raising your metabolic rate, even if you’re not working out. There is however one other form of exercise I didn’t talk about, as well as that is strength-centered weight training exercise. Eating a lot of convenience-sort food items like sausages and fast food when you're on the run can impede your fat loss. You ought to psychologically make on your own to satisfy these long-term obstacles prior to beginning your vacation to weight-decrease. More modern day Federal Institution for Health and also Proper care Quality assistance suggests that a 3Per cent weight-decrease is desired as well as needs to be the achieve a 12-full week assistance 1. Quite basically, your weight-decrease ambitions should be distinct, quantifiable, feasible, practical and tangible. To shed visceral extra fat, you ought to acquire inside the appropriate food, consume lots of drinking water and also do lots of physical physical exercise. Visceral body fat stands out because the kind of body fat that encompasses the internal organs in your very own abdomen and makes your belly appear bigger than it might really be. A 5-year examine on minorities ranging in age from 18 to 81 showed that in case you include dietary dietary fiber to the diet plan, as well as combine it with physical physical exercise, you are able to speed up visceral weight-reduction. By carrying out this, you won’t have to wonder precisely what to consume for the following meal, or be worried about producing a calorie debt. Operating aids you protect a calorie debt by expanding the amount of calories you burn. It's possible to enhance your calorie debt and your rate of body fat decreasing - no less than theoretically - by consuming much less. Research from the American Heart Organization indicates that skipping foods for body fat decreasing ultimately backfires. Practical Fat burning Targets: A Real Possibility Verify You Need Even however, if we made a decision to dance to get leaner, we must set a goal. For example, it could be a lot more realistic establishing a objective of ingesting some fruit every single day rather than one sweet object. Each time we established a objective, we attempt to calculate the near future, which is absolutely difficult. Which can be undoubtedly a issue you need to think about when creating Revitaa Pro approach. Some people call it “deep belly fat,” and it’s been linked to all kinds of problems including insulin resistance, coronary disease, diabetes, and cancer. Cortisol can also make your insulin level spike triggering your blood sugar to drop and making you crave sugary or unhealthy goodies. Yet another consists of fasting every day for 16 hours and also eating all your food within an 8-hour period. Other cells are then within a situation to use these fatty acids as gasoline. Omega 3 fatty acids happen to be in greasy fish, also as consuming 2-3 helpings of fish every week is required. Coconut oil makes up higher essential essential fatty acids of the moderate length generally typically generally known as medium-sequence triglycerides which may improve satiety correct shortly after food. With balanced meals choices and a little exercise if you’re capable, you might be in a position to achieve your body fat reducing and physical fitness goals each in the brief and long-lasting. In order to reduce bodyweight, different methods, like diet program, actual physical physical activity, medication therapy, also as surgical treatment have currently been advised. Exactly how several calories you need to consume a day to reduce bodyweight will rely on several components, also as your age, sex, accurately how significantly weight you need to decline, and your action level. Revitaa Pro boosts your metabolic process and also calms your opinions, empowering you to rest properly, that is furthermore vital from the extra fat decrease method. Revitaa Pro though a pretty new extra fat decrease supplement inside of the town but with offers to aid you drop more lbs and also raise your metabolic process in spite of how old you are or full system framework.
How COVID-19 Impacted on Nutraceutical Packaging in Healthcare Industry ?
COVID-19 Impact on Nutraceutical Packaging in Healthcare Industry The COVID-19 pandemic has impacted the food and beverages industry including the nutraceutical market by up surging in their consumption globally. Each and every segment of nutraceutical industry has been impacted either positively or negatively due to the COVID-19 pandemic. The Nutraceutical packaging market is subjected to have the positive impacts due to the sudden outbreak of COVID- 19. This is mainly due to the consumer awareness about the importance of consuming the nutraceuticals in order to boost their immunity to fight the pandemic period. The demand for the nutraceuticals has been increasing across the globe due to the changing lifestyle of the health conscious consumers. This increase in the demand for the nutraceuticals have positively affected on the nutraceutical packaging market. AFTERMATH OF COVID-19 AND GOVERNMENTS INITIATIVE TO BOOST THE GROWTH OF THE MARKET The aftermath of the COVID- 19 has a very positive impact on the market of the nutraceutical packaging across the globe. As the consumers are more incline to buy health and wellness products such as nutraceutical products which further increased the sales and revenue of the market players. The post pandemic period people are more concerned towards the product’s safety and shelf life which further drive the demand for advanced and innovative packaging materials for nutraceuticals. Also, with the growing awareness and growing social media nutritional trends influencing population all around the world will increase drive the demand for nutraceutical which will further boost the growth of global market. Many governments have taken initiatives for the nutraceutical packaging as they have been focusing on ways to improve the consumer’s health and wellness. The government initiatives to support industries in order to manufacture innovative packaging products will boost the growth of the market. For example, · European Union (EU)- funded project NanoPack aims to develop packaging solutions that increase product life after packaging by using novel anti-microbial surface application on the food packaging product surface. The Nanopack antibacterial film extends the shelf life of the product by two days. This two day increase in shelf life increase product stability by 40%. Therefore, such initiatives taken up by the governments which aim to help the manufacturers to manufacture safe products for the nutraceutical packaging will propel the growth of the market. STRATEGIC DECISIONS OF MANUFACTURERS AFTER COVID-19 TO GAIN COMPETITIVE MARKET SHARE To deal with the COVID-19 outbreak challenges many nutraceutical packaging market players are creating new strategies. It is predicted that these strategies are providing high chances to escalate up company revenue and its growth in the forecast period. Similarly, growing opportunities in innovative packaging solutions is attracting a larger consumer base for the nutraceutical packaged products. Increase in the demand for the nutraceuticals has made companies to launch the new products in spite of the COVID- 19 challenges and to gain a larger market share. Despite of the COVID – 19 pandemic outbreak, the manufacturers have been creating new opportunities by themselves by participating in exhibitions in order to spread the awareness about the nutraceuticals and their nutritional benefits which helps in boosting the immunity of the consumers. For instance, · In 2021, MJS packaging announced that they will exhibit for the first time since the start of COVID- 19 pandemic at the 2021 Cannabusiness international market place Michigan summit and expo in Michigan. Therefore, such product launches, exhibition of the products at the expos and vents in order to increase their consumer base are the strategic decisions which are taken up the market players to gain larger market share. PRICE IMPACT The COVID-19 had a terrible impact on the global economy. Many establishments have to remain shut while others scale down their operations or put on hold expansion plans as they survive the unprecedented crisis. The other impact of the COVID-19 pandemic outbreak is the delay or fluctuation of raw material supply for nutraceutical packaging manufacturing. This fluctuation has resulted in increase in price of raw material, which has impacted the prices of nutraceutical packaging products. IMPACT ON DEMAND There is a rapid increase in demand for the nutraceuticals increasing popularity for the nutraceutical packaging as well. Demand for the increased shelf life of food products across the globe is expected to increase the growth of the market in the COVID-19 period as well. There is an increasing consciousness about health and weight management is playing a crucial role in the demand for the global nutraceutical packaging market. On an average, the consumers have increased have increased their monthly spending on vitamins, minerals and supplements products by 10-15% since the COVID- 19 began. The increase in the awareness among the consumers about the consumption of the nutraceuticals is that they can build the immunity that is highly required in the COVID- 19 pandemic period has positively affected on the nutraceutical packaging as well. With the rise in the consumption of the nutraceutical in order to maintain the good health and fitness, the demand for the nutraceutical packaging also increased. Therefore, there has been a constant increase in the demand for the nutraceuticals which positively affected on the nutraceuticals packaging market as the packaging of the vitamins, minerals and other dietary supplements is the major factor that attracted the attention of the consumers. IMPACT ON SUPPLY CHAIN During the pandemic situation, the supply chain was majorly disrupted due to a lack of resources and transportation. Also, the governments across the world have implemented various restrictions and lockdowns to prevent the spread of the disease. In the same way, many governments have restricted the movement of goods across the countries and the entire supply chain was distorted. Owing to the disrupted supply chain, the transportation of raw materials has been interrupted and the production of nutraceutical packaging products was halted. Similarly, the manufacturers aren’t able to visit the customers such as nutraceutical companies to provide them with the packaging materials due to the implementation of lockdowns across the various parts of the world. Thus the demand for nutraceutical products has been tremendously increasing whereas the packaging materials production has been disrupted. As a result, the COVID- 19 pandemic has negatively impacted on the supply chain of the nutraceuticals packaging market. CONCLUSION COVID- 19 pandemic has taken a toll on the population and economy. A collaborative effort on governments, public health departments and hospital fraternity to fight corona virus has led to the economic slowdowns, lockdowns and extreme public safety measures. Due to the increasing health conscious ness among the consumers, the demand for the nutraceuticals has been increasing constantly in the COVID – 19 pandemic periods. This is mainly because of precautionary measures which are followed by the consumers for the COVID-19 which in involves the intake of nutraceuticals. However, the supply chain has disrupted during the outbreak scenario because the demand is more for these products. As unlocking of the lockdown being started in various regions of the world, it is expected that the supply chain became normalized for the market.
How COVID-19 Impacted on Oral Care in Healthcare Industry ?
COVID-19 Impact on Oral Care in Healthcare Industry OVERVIEW The COVID-19 pandemic has posed a complex challenge in front of several healthcare companies and proved to be an unprecedented global health threat. This global pandemic has emerged in December 2019 which has been proved as a global pandemic by WHO in March 2020. With the development and introduction of novel coronavirus vaccine, COVID-19 cases have been declined but with the development of mutant coronavirus strain, the overall COVID-19 cases have been surged and are increasing at a rapid rate in India, and the U.K, and other European countries. The most common symptoms associated with this include cough, fever, diarrhea, sore throat, and loss of smell or taste. Patients affected with COVID-19 are at increased risk of developing hepatic manifestations and also experiences damage to liver tissues. COVID-19 has led to the closure and reduced hours of dental practices except for emergency and urgent services, limiting routine care and prevention. Dental care includes aerosol-generating procedures that can increase viral transmission. The pandemic offers an opportunity for the dental profession to shift more toward non-aerosolizing, prevention-centric approaches to care and away from surgical interventions. Direct effects of COVID-19 on oral health include ageusia (an official symptom of COVID-19) and case reports of vesiculobullous lesions and necrotizing periodontal disease. oral care product has a wide portfolio such as breath Fresheners, Mouth Wash, Dental Floss, among other products. The Article here shows the impact of COVID-19 on the oral care market. IMPACT ON PRICE As the mouth is an important place for bacterial colonization due to which it is necessary to use the product for oral hygiene. With the sudden increase in COVID-19 cases, people's concerns for better health had also increased and the link between oral health and COVID-19 infection also expand the health to oral. As India relies on China for 70% of API’s intermediates and bulk ingredients, COVID -19 is expected to hike the price of the ingredient used for an oral care product For instance, · In the year 2021, As Proctor & Gamble announced the third-quarter result in which the net sales increase by 5 %, and also mentioned that they are planning for a price hike in certain product divisions. This step is taken seeking to recover the revenue loss during COVID-19. · According to GlaxoSmithKline plc, the cost of dental consultation and treatment was cited as the concerning factor IMPACT ON DEMAND The coronavirus has affected the various regions of the world and caused the widespread closure of companies and local manufacturing plants. This lockdown and isolation have adversely impacted global economic activity. As studies around the world have shown the improving oral hygiene is expected to increase the chance of generating demand for the product. THE IMPACT OF COVID-19 INFECTION ON ORAL CARE The rising awareness of oral hygiene COVID-19 has increased the demand for a product requires for oral care as the increasing studies for SARS-COV-2 indicated that proper oral hygiene has been reported to decrease the chances of infection which increases the demand for mouth wash, oral povidone solution, novel gargle solution. · However, due to restrictions and aims to reduce COVID-19 transmission, 30% of respondents had visited a dentist less frequently during the pandemic The second cause of increasing demand for oral care products is that approximately 90% of the product used in oral care are over the counter which can be added as the plus point in maintaining the demand for oral care products. The market players in oral care are also focused on the research to bring novel products to interstate commerce. For instance, · Microbac Laboratories, an independent and internationally accredited testing facility worked on behalf of Unilever Research Laboratories, has found that rinsing with mouthwash containing CPC Technology for 30 seconds is effective in reducing the viral load of SARS-CoV-2, the virus that causes Covid-19, by 99.9%. This type of research surge the demand for the oral product · Colgate-Palmolive President mentioned in an interview that they have seen elevated demand for oral care related to viruses, which also boosted the innovative growth related to a premium product This suggests that the increasing prevalence of COVID-19 poses precautionary measures due to which the global population started to take concern for their health hence enhance the demand for oral care. This thus signifies that COVID-19 is accelerating the demand of the oral care market. IMPACT ON SUPPLY The COVID 19 pandemic has affected and badly disrupted the global drug supply chain due to the continuous shut down of manufacturing facilities and restrictions imposed by the government over import and export activities. As per global sources, it was found that the beauty care business is still facing a crisis due to COVID-19. However, oral care market players are in a strong position. The two main leaders Colgate-Palmolive and Johnson and Johnson had seen a lift in sales in Q1 2020. Colgate-Palmoliva has net sales of USD 415 million for Q3 2020, up by 5.5% from the previous year. The surge of demand for oral care increased during COVID-19 however, the global restriction, and state-wise travel restriction has caused challenges for the market player. Moreover, there are many local players also in the oral care market that continued to fulfill the demand in case of any disruption. Oral care is categorized under essential need products which leads to the easy flow of these products. The main challenges during the pandemic is the supply of API’s and Ingredient or excipient used in toothpaste, as China holds the major share in API’s and other chemicals used in oral care and global restriction has somehow affected the supply chain for these products too. This, thus signifies that due to continuous lockdown and several restrictions by government authorities the companies and patients are facing disruption of the supply chain for oral care. However, oral care is categorized under essential care which lowers the effect of supply chain disruption during COVID-19. STRATEGIC DECISIONS OF MANUFACTURERS Collaboration, agreements, strategic initiatives, product launches by market players such as Colgate Palmolive, Hindustan Unilever among others in the oral care market will help them to expand their product portfolio and to provide appropriate products to the consumer. This in turn will lead to increased product sales and hence will put a positive impact on the overall company’s revenue. Oral Care product manufacturing companies are taking so many strategic decisions to cope up with the current scenario of COVID-19. The companies engaged in the manufacturing of toothpaste, mouth wash, gargle solutions among others are adopting several initiatives to accelerate the development of newer products and efficiently supply the product to different end-users. Companies have done collaboration and product launches between 2019 -2020 which supports the sustainable growth in the oral care market For instance, · In September 2020, Colgate Palmolive launched as first-ever vedshakti mouth protect spray, seeking their focus on oral hygiene during COVID-19. · Hindustan Unilever also planned to launch a mouth wash with 99 % in reducing SARS-COV-2 virus and has recently shared the preliminary data. · In April 2020, GlaxoSmithKline Consumer Healthcare Limited (India) merged with Hindustan Unilever Limited (HUL), with HUL responsible for the distribution of GSK’s Consumer Healthcare brands in India, including its leading oral healthcare brand, Sensodyne. · In April 2020, Perrigo Company plc (Ireland) completed the acquisition of the oral care assets of High Ridge Brands (US), which includes Dr. Fresh, LLC. · In December 2019, Colgate-Palmolive Company launched Colgate Optic White Renewal Tooth Paste. · In 2020, Colgate-Palmolive comes up with a recyclable toothpaste tube which will increase the interest of the population and surge the demand for the product leading to growth in revenue of the company Thus, companies operating in the oral care market are adopting several strategies, including collaboration, agreements, acquisition, and market expansion to enhance their business. These strategic decisions by the companies are expected to provide significant opportunities for the market players operating in the oral care market. CONCLUSION As the pandemic of COVID-19 has resulted in several restrictions throughout the borders but still, manufacturers of oral care can manage their stocks. Various manufacturers have allowed their manufacturers to work in a clean and safe environment to boost up the production of oral care categorized under essential need products at various manufacturing facilities across several regions of the world helping them to maintain a continuous supply chain. However, a decrease in doctor’s visit has impacted the market but the majority of products used in oral care are over the counter product which leads to continuous demand for oral care, and by raising the prices the companies are gaining extra profit which is helping them to combat the negative effect on overall revenue.
How COVID-19 Impacted on Parenteral Nutrition in Healthcare Industry ?
COVID-19 Impact on Parenteral Nutrition in Healthcare Industry The COVID-19 pandemic has influenced the whole planet with its major impacts on the economy and businesses across the globe. The COVID-19 spread worldwide in unprecedented ways due to its high infectious and contagious nature and lack of availability of its vaccine. As a result, the greatest medical challenge in the 21st century is yet to be faced by physicians worldwide. Though the emergence of the virus can be traced back to Asia, many European countries along with the U.S. have been struck massively by the pandemic. The virus has spread across all regions ranging from North America, Europe, Asia-Pacific, Middle East, and Africa up to South America. The COVID-19 has been declared as a pandemic by World Health Organization (WHO) due to its increased spread across the globe. After the declaration of the pandemic, various countries announced the complete lockdown such as India, China, and other Asian countries to decrease its spread. According to the latest situation report by World Health Organization (WHO) stated 175 million cases of Corona have been reported globally and 4 million patients are dead due to the coronavirus. On a slightly positive note, a total of 158 million people have recovered and a total of 2 million vaccine doses have been administered as well. Parenteral nutrition is the medical term used for infusing a specialized form of food through a vein, intravenously. The objective of the treatment is to correct or prevent malnutrition by providing liquid nutrients, including carbohydrates, proteins, fats, vitamins, minerals, and electrolytes. Parenteral nutrition is used when the patient's gut cannot be used to absorb nutrients, the nutrition then must be delivered into the patient’s bloodstream, bypassing the gut. The reason for this type of feeding includes blockage of the gut, Perforations of the gut, parts of the bowel are diseased, or when a large part of the gut has been removed. COVID-19 has negatively impacted the market as trained professionals are required for the administration of such nutrition. But owing to the imposition of lockdown by the government, such administrations can’t be done that impacted negatively. The pandemic has affected the parenteral nutrition market in three ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets. For instance, · In October 2020, the American Society for Parenteral and Eternal Nutrition issued the guidelines to update the use of filters for parenteral nutrition. The guidelines aim at reducing exposure to particulate matter during parenteral nutrition (PN) therapy by updating In-line intravenous filters. IMPACT ON DEMAND With the lockdown, all hospital admissions were stopped except the COVID-19 patients. Since the pandemic, lockdown situation the economic growth of the country is declining. And the manufacturing units for various items that are considered non-essential are shut down due to the non-availability of manpower. The pandemic has caused major destruction in the delivery of healthcare products across the world. It has posed limitations on many patients to access standard health services such as visits to healthcare professionals, medications, and diagnosis. It has adversely impacted the ability of patients and practitioners to adhere to treatment guidelines. Moreover, the demand for parenteral nutrition and growing awareness about current and new products is also fueling the market. For instance, · Otsuka Pharmaceutical Co. Ltd stated that in the pharmaceutical business, official requests to stay at home and urban lockdowns have led to a decrease in outpatient numbers in hospitals but there is an upward trend for long-term prescriptions for patients with chronic diseases. If the current situation were to be prolonged or become more serious, there may be a further decline in the number of new prescriptions and decline in prescriptions such as injections as part of hospital treatment due to restrictions on visits to health care facilities and the voluntary restraint on efforts to raise awareness of diseases, which may affect revenue. However, the negative impact of the pandemic on the parenteral nutrition market will be soon mitigated as different states/ countries allow medical clinics to reopen, services and once again being offered. IMPACT ON PRICE Due to the pandemic, the market is disturbed to a greater level. The several establishments have to remain shut while others scale down or put on hold expansion plans as they tried to survive the unprecedented crisis. Due to the impact of the coronavirus, many large pharmaceutical companies have placed new trials on hold and numerous small, mid-size, and large enterprises have suspended ongoing ones, thereby demonstrating the magnitude of the disruption. There have been uncertain past months due to the emergence of COVID-19. The sale of some company’s products experienced a downfall while others managed to stay afloat. For instance, · According to the annual report of Vifor Pharma Management Ltd., the sale of its products increased from USD 1794 million in 2019 to USD 1944.4 million in 2020 · According to the annual report of Otsuka Pharmaceutical Co. Ltd the nutraceuticals segment had a sale of USD 3,340.88 million with a business profit of 2.1 %. The total revenue in 2019 was USD 13,962.4 million which increased to USD 14,228.26 in 2020. As this lockdown has put manufacturers and distributors in worry as the key materials for the product, especially raw material supply are hindered; it will surely lead to change in prices up to an extent. IMPACT ON SUPPLY CHAIN As the world came to halt in the last few months due to the emergence of the pandemic, the supply chain couldn’t escape the impact. The government throughout the globe imposed total lockdown which led to supply chain disruptions. Consequently, the supply chain came to standstill due to the closure of borders. Even though the demand for parenteral nutrition remained untouched up to an extent, the availability was affected due to disruption in the supply chain, trade, and travel restrictions. Supply of raw material was also affected, due to which the product was affected. The outsourcing services which are providing warehousing, storage, and other services face challenges too. They are dependent on the logistic and transportation of chemical compound raw material from the outsourced service to the researchers' desk. However, with the sudden shut down globally with a ban in travel this process gets disrupted. Still, the companies managed to overcome the challenges and saw high growth. For instance, · According to the Annual report 2020 of Otsuka Pharmaceuticals Co. Ltd stated that concerning the procurement of raw materials, the purchasing channels overall are secure, although delays are occurring for some important items. Manufacturing had been temporarily suspended for some line items due to employees staying at home, but all manufacturing has been restored. The manufacturing operations are adequately staffed and proceeding smoothly. If the spread of COVID-19 were to be prolonged or become more serious causing stoppages in the procurement of raw materials, or if a cluster of infections or other similar cases occurred at a manufacturing plant, the supply of certain products may stop. However, the companies have been faced with substantial business and operational disruptions, which have included everything from mitigating the effects of reduced supply to managing disruptions to logistics suppliers, and indeed hurdle in meeting their contractual obligations to customers. The pandemic has forced the companies to rethink their supply chains and their stability and reliability for an uncertain future, including other externalities and government actions throughout the world, which have begun impacting supply chains, such as issues of sustainability. STRATEGIC INITIATIVES BY KEY PLAYERS As the reality of COVID-19 dawned upon the world, manufacturing and production unit of companies involved in parenteral nutrition key players formed strategies to mitigate with the limitations occurred due to the virus and keep their business running At the individual company level, companies are now more focused on operational resilience and accelerating initiatives that enable more agility, and transparency through the greater deployment of analytical tools and automation. Companies are considering re-evaluating their strategies, risk tolerance, and overall footprint. The market players have adopted various strategies including mergers, acquisitions, partnerships, and new product developments, among other strategies, to stay ahead of the competition and expand the market footprint. For instance, · In May 2021, Otsuka Pharmaceutical Co. Ltd announces that its affiliated company, Egypt Otsuka Pharmaceutical Co., S.A.E. (Egypt Otsuka), has agreed to jointly participate with a local pharmaceutical company Gypto Pharma for Trading and Pharmaceutical Manufacturing S.A.E. (Gypto) to establish a new company, Otsuka Gypto Pharmaceutical Egypt S.A.E. (Otsuka Gypto), which will sell ethical drugs such as IV solutions locally. However, to address the crisis all companies in this market are revisiting their financial trajectories and framing new strategies that will lead to bringing out solutions in the market resulting in increased business efficiency. CONCLUSION COVID-19 has impacted every sector with no exception global parenteral nutrition market has been affected the same. Different companies dealing in parenteral nutrition were finding out their way to deal with this pandemic situation. The government and companies around the globe are working together and have issued advice for those undergoing treatment for severe conditions during these unprecedented times during COVID-19 lockdown around the world. However, in the crisis call pharmaceuticals, key players, government bodies and healthcare organizations are working closely with healthcare professionals, customers, and patients for the betterment of public health. Thus, it is reasonable to assume that constraints on gathering and movement have disproportionally impacted people who use parenteral nutrition. However, healthcare industries and government bodies are exclusively concentrating on how they can make the effective and best contribution to control the spread of the virus and save lives. They are also ramping up the production of essential medicines to new levels and ensure that the speed doesn’t affect or destroy the quality of products.
COVID-19 Impact on Healthcare Robots in the Healthcare Industry
COVID-19 Impact on Healthcare Robots in the Healthcare Industry As the deaths from the COVID-19 pandemic start to increase, the World Health Organization (WHO) has urged citizens to maintain specific social distances. In an attempt to avoid the spread of COVID-19 at the population level, medical robots or healthcare robots are gradually involved in the roles of sanitizing patients' quarters, distributing medications, and supplying meals to ill people. Supplying supplies to households and delivering effective services to injured patients remained a major obstacle, and this is where healthcare robotics is creating a space for them. The new pandemic is growing in demand for healthcare robots as they play a crucial role in the process of drug distribution, patient evaluation, and medical workers' infection control. COVID-19 Market Effect The 2002-2004 SARS pandemic has indelibly altered the business climate for healthcare robots. Nearly 8,000 people were affected and 700 were killed. In addition, MERS affected 200 and killed about 40 of them. They were all limited to different territories. COVID-19, on the other hand, as a pandemic, has had a larger influence on the global economy. The SARS and MERS outbreaks contributed to a new era of creativity with the advent of disinfection robots that produce UVD light to combat against infectious viruses and bacteria on hospital surfaces. If COVID-19 continued to grow globally, UVD robots makers would expand significantly, and if the pandemic was bought under control, healthcare robots would be developed exponentially to decrease the risk of infective infection in hospitals. The healthcare robots market was expected to hit with a significant growth rate in 2020-2021. Owing to production reductions and supply distresses, the healthcare robotics demand was minimally affected in 2020. That would contribute to a decline of BPS 180. But the sector is now starting to see blue sky as the main development region such as China is beating the recession and moving up. Succeeding in the Wake of the Emergency Healthcare robots can play a critical role in the current pandemic by reducing human involvement and shielding health staff from infection. This will involve measuring patients' temperatures, disinfecting equipment, measuring specimen swabs and delivering much-needed psychological assistance to patients in isolation. Researchers are now beginning to illustrate the cyclical aspect of technology right after the recession. The COVID-19 contraction would accelerate labor-replacement automation as business sales see a fall. This might have arrived during the 'cultural shock' as automation eliminates low-skilled jobs. The prospects for healthcare robotics exist in the introduction of smart navigation and the detection of high-risk and highly contaminated environments. Wireless networking systems in healthcare can include drones, telemedicine, and decontamination with AIdriven capabilities. Healthcare robotics should see early acceptance in regions first hit by the infection, offering them an advantage. The companies in China are now doubling their revenue production from the previous years. By the time the pandemic is done, robotics should be distributed through a variety of facilities and programs. The manufacturing will experience reshoring, with decreased reliance on countries such as China, and one way to do so would be by robots that would support the robotics industry. Disinfection Robots UVD Robots, a Danish corporation located in the University of Odense and Blue Ocean Robotics, is a leading manufacturer of disinfectant robots for China in the fight against the spread of the virus. The firm signed a deal with Sunay Healthcare Supplier in February and has since delivered dozens of its self-driving robots to clean hospitals and other places with ultraviolet light. The firm claimed that this reduces the transmission of coronaviruses without exposing medical workers to the possibility of infection. Since then, the firm has marketed robots to locations in more than 50 organizations, extending its services outside China to places in Europe and the United States that are facing epidemic issues. UVD Robots frequently accepts inquiries from outside the hospital and medical institutions, including prison, offices, production floors, department shops, malls, airports, hotels, and restaurants. Dimer, located in Los Angeles, provides its GermFalcon UV-C robotics equipped to clean aircraft and its UVHammer robotic systems for hospitals and complex settings. In mid-January, the organization provided its services to the first three major U.S. airports where Chinese arrivals took place. Xenex confirmed that its LightStriken germ zapping robots became the first hotel in the U.S. to sanitize or clean guest rooms and communal areas at the Westin Houston Medical Center. The technique developed by two epidemiologists in Houston will easily kill pathogens, bacteria and fungi by utilizing strong pulsed xenon ultraviolet radiation. The MTR Company, which runs the Hong Kong subway, has confirmed that it is partnering with Avalon Biomedical (Management) Limited to build the VHP Robot, which stands for the vaporized hydrogen peroxide system. The robot conducts deep cleaning and decontamination in train compartments and stations to secure passengers and workers. More than 30 disinfection robots developed and manufactured by TMiRob, a company in Shanghai, have joined major hospitals in Wuhan, the hub of the novel coronavirus outbreak, to counter the epidemic. The white robot deployed by the firm has a hydrogen peroxide sprayer on its "front" and nine ultraviolet lamps in its "belly" and can conduct various types of disinfection in areas where humans and machines coexist, navigation hardware allows the system to clear hazards independently. Beijing-based robotics firm CloudMinds sent 14 robots to Wuhan, China, to assist with medical treatment in the wake of the coronavirus pandemic. Robots, some of which are more humanoid than others, can scrub and disinfect, distribute medications to patients and check the temperature of patients. CloudMinds contributed robotics to a number of medical institutions in China, including the Wuhan Wuchang Smart Field Clinic, which was converted from the Hong Shan Sports Centre. An Israeli-made AI robotic assistant is being used in hundreds of clinics, community centres, nursing homes and industrial buildings in Asia to eliminate human-to-human interaction as millions of people take precautions for a current coronavirus epidemic worldwide. Israeli company Robotemi, a creator of the Temi robot assistant, claims the device has already been sold to hundreds of locations throughout South East Asia, including China, Japan, South Korea, and Hong Kong. Healthcare Assistance Twelve sets of robots were provided into an intelligent hospital in Wuhan, China by CloudMinds, a supplier to A3, to support the health workers overstressed and threatened. The robots carried out many important tasks including flagging patients who had a temperature, pulse rate, and blood oxygen rates and medicine at the entrance to the field hospital. Such robots have also cleaned and disinfected the hospital areas and performed fitness exercises for patients with the disease. In addition, Chinese researchers modeled the arm of a robot on wheels that can ultrasound, swab in the mouth, and hear the noises produced by a patient's organ normally with a stethoscope. The robot will conduct these activities with cameras in the same space without having to provide medical staff. Professor Zheng Gangtie from the University of Tsinghua developed the device. Unmanned Vehicles Unmanned vehicles and other autonomous robots are deployed in China's virus-affected regions. For instance, Beijing JD Logistics has sent two unmanned L4 class vehicles to Wuhan, and engineers have driven the vehicles remotely through the cloud. Another firm, Idriverplus, has donated an unmanned transportation vehicle to Shanghai and Beijing hospitals. Amazon revealed that it will recruit 100,000 workers to deliver products in vacant warehouses to purchase during the epidemic. The area of e-commerce is now growing with the usage of robots to fill orders and this increase is projected to accelerate as more customers shop digitally, while they remain home more. Teleworking Robots The use of video and audio conference software as companies including Zoom, Microsoft (Skype) and others providing interactive meetings services has expanded with millions of citizens still operating at home because of the state and nation lockdowns. However, businesses of telepresence robotics do have greater interest of their apps, but not for the same purposes. As a consequence of the latest epidemic of coronaviruses, Ava Robotics is building handheld telepresence robots for many years. According to the CEO and cofounder of the firm, the increasing number of hospitals and nursing homes are interested in the robots, which enable the family to talk to patient and older residents on video as a consequence of the policy of 'no visits' and lock-outs in these places. Owing to the need to be simple to use on one end of the line-an aged or ill user in this situation, Ava robots are distinct from the machine enabled video-conferencing device used on a phone or a computer. The company works to make it simple for robotics setup people to click on a connection and talk to the telepresence robot instantaneously. In parallel to the robot's operation, hospitals have utilized Ava robotics, primarily for triaging through the coronavirus. For starters, the robot is configured to remotely test patients with Ava robotics after the initial appointment in one of Boston's largest hospitals. It's also the machines that patients use to reach and depart a position often-rather than people, the system will do it to save the medical equipment because a person has to wear a face mask, shoes and gloves every time instead of human operation. Initially, Czartoski, a practicing neurologist, was utilizing telemedicine in the care of stroke survivors, one of the strongest early lead for telemedicine. According to him, "If I encounter anyone with stroke signs, I will test them with a camera relatively easily to inform them if there is left side fatigue to speech problems, then I will look at the CT scan and the results then make a recommendation for the ER specialist." Virtual visits are growing in the providence. The non-profit health care network conducted nearly 100,000 virtual appointments in 2019. In 2012, the providence carried out a few hundred telemedical visits a year and was rising at a fast pace — from 12,000 in 2016 to 41,000 in 2018 to more than 100,000 last year. That figure does not explicitly reflect the usage of telemedicine in the ICU. Pharmaceutical Assistance Pharmaceutical firms tend to work on viral vaccinations or therapies and automation businesses have developed electronic tools to further simplify manual and replicate processes over the years. The robotics firms also provide options for businesses seeking to combat the COVID-19 virus. The two new modular, ready-for-assay workstations, focused on the Microlab STARlet liquid handling system, were announced recently by Hamilton Group. The latest technologies will help render the SARS-CoV-2 coronavirus that triggers the current COVID-19 quick and highly effective diagnostics, and research-based testing, said the firm. The MagEx STARlet allows the extraction of biological samples from high-performance RNA-based magnetic beads, the PCR Prep STARlet workstation is pre-configured and eligible for sample deployment utilizing recent protocols from the centers. Furthermore, the robotics designed by businesses is actually being employed in the war against coronavirus. ABB robots can be seen in this ABC news story to help a medical laboratory with the development of COVID-19 research kits. Healthcare Robots Market Synopsis The new pandemic will be targeted by health-care device vendors. They will be aligned on developing, unregulated markets with tech firms, stressing the value for national emergencies of healthcare robots. Many industries such as Enterprise Resource Planning (ERP) for higher profit margins are often impacted, in combination with robotics. Medical personnel's are predicted to become a potential phenomenon in patient events, raising the incidence of disease infections. According to the International Federation of Robotics (IFR), the shipments of medical robots already have increased by 50% in 2018. The outcome of coronavirus, however, illustrates some of the essential situations in which robotic systems may be disinfected, tracked, controlled and supplied. The World Robotics study shows that Europe is the most robot-densely inhabited region in the world with an estimated size of 114 units per 10,000 employees. In Edinberg in the United Kingdom, robotic engineers are operating on what they believe is the first safety device to speak to more than one human concurrently. The initiative was planned to support disabled citizens. Scientists say that the discovery will aim to counter potential waves of diseases such as the pandemic. Throughout the United States, the COVID-19 patients are housed at the Providence Community Medical Center throughout Washington in remote locations with two rooms. A robot, which has a microphone, a stethoscope and a camera, is being used by physicians. It helps doctors to interact individually with patients without touching. Disinfection UVD robots in China has been widely searched after as a consequence of the outbreak. The robot built by Denmark's blue ocean robot is ordered by a significant number of hospitals in the world. In the epidemic epicenter of the Wuhan outbreak, these robots played an important part. As time passes, robotics plays a significant role in fighting diseases such as COVID-19, similar to other technologies. Robot technologies will play a significant role not just in aiding patients but also in maintaining the wellbeing of physicians and healthcare staff in the case of an epidemic. The crises are changing views on what is feasible in terms of innovation and strategic intervention on the part of both private and policy players. When the COVID-19 pandemic is finished, the variety of technologies and industries are built into robotics. The virus was a successful chance for businesses to show robotics for public applications. One of the most common is the installation of mobile unmanned ultraviolet (UV) light platforms to disinfect facilities. Danish business UVD Robotics is taking advantage of this potential and is increasing the application of robotics to clean hospitals. The U.S. based Germ Falcon provides identical UV disinfection approaches for airplanes, while Chinese TMiRob deploys UV disinfection robots in Wuhan. "Automation of disinfection is a vital aspect of preserving health and safety and maybe one of the big bright points in reaction to COVID-19. In the near term, the policymakers would need to improve their defense apparatuses as well as the effectiveness of their medical services in order to implement quarantine mandates. The robots should be crucial to doing this by disinfection, tracking and surveillance. Throughout the long run, COVID-19 is contributing to a major reassessment of the worldwide supply chain in production. America's reliance on Chinese imports of essential machinery and drugs is becoming a controversial problem, and policy officials are now seeing the crisis as an incentive to revitalize the drive to re-launch more manufacturing resources on the domestic sector. Whether that turns into more drastic intervention by policymakers to diversify or re-land the output of key products, it may very well bode for the robotics sector, because these reforms will entail substantial rises in CAPEX and efficiency gains in developing countries. Instead of the infectivity of COVID-19, it is better if human-to-human interaction is minimal. Since robots are free for contamination, software companies such as and others have invested to get more robots marching down the main street to provide medical equipment in healthcare settings. The robots often end up becoming critical when providing vital items to individuals who order and purchase digitally and are lonely at home. Meituan Dianping, a logistics platform, is growing the 'contactless shipping' choices by automated vehicles and robots. Shenzhen-based company Pudu Technology aimed to reduce cross-infection by introducing a robotic home distribution of medications and food. COVID-19 poses a nightmare for robotic manufacturers designing applications for emerging economies in the automotive, construction and supply chain industries. But for vendors targeting markets which that are closer to government, such as safety, education, and protection, this is a great opportunity. Whitton advises that 'the market players create tailored solutions for non-manufacturing use cases or aim to create integrated solutions to allow scale-up in the manufacture of medical supplies. To mobile robotics manufacturers and tech firms pursuing more global markets, this is a perfect chance to demonstrate the role of healthcare robotics in solving national crises as well as alleviating economic shock.
Significant COVID-19 Impact on Nivolumab in Healthcare Industry
COVID-19 Impact on Nivolumab in Healthcare Industry COVID-19 (Coronavirus) has affected the day-to-day life of people and has slowed down the economies worldwide. The pandemic has affected millions of people who either got sick or died due to the spread of this disease. Within a few months, coronavirus disease (COVID-19), which originated from China, became a pandemic, with more than 30 million people being infected till date. There are now numerous vaccines in use. The first mass vaccination program commenced in early December 2020, and as of 15 February 2021, 175.3 million vaccine doses have been administered. There is an added complexity because of COVID-19 diagnosis in cancer patients, particularly while on active treatment with immunotherapy like nivolumab. COVID-19 could cause more harm to cancer patients. In order to prevent the infection from spreading, the patient’s number and new diagnosis have been less during the COVID 19. The COVID-19 pandemic has led to a dramatic loss of human life worldwide and presents an unprecedented challenge to public health, food systems, and the world of work. Still, there is an increase in the demand for cancer treatment with immunotherapy drugs like nivolumab during the second quarter of 2020 with the rise in awareness regarding health and new product launches in countries. IMPACT ON PRICE COVID-19 is significantly decreasing commercial activity in every area of the business sector. The economy has been decreased during the pandemic with the restricted and disrupted supply and sales of products and devices. The cost of medication and treatment of nivolumab has been increased due to the increasing demand for this drug during COVID-19. This contributed to the increased expenses and prices of immunotherapy drugs. Changes in the economy and other factors have caused consequences, including the decrease in the sales of the drug in some countries such as the U.S. With the rise of COVID-19 and decrease in new patients has also contributed to the increased cost and priced of some products and medication. · The price of Opdivo (nivolumab) drug which is a most common therapy treatment for various type of cancer or tumor have been increased to USD 1,172 for a supply of 4 milliliters of injection in 2020 with the rise in demand and increasing patients population in the second quarter of 2020. IMPACT ON DEMAND Global economic development in 2020 has been severely impacted by the COVID-19 pandemic. The COVID-19 has given rise to risks such as a prolonged, significant decline in global demand as well as unfavorable geopolitical and macroeconomic effects. The coronavirus pandemic has provoked many strategical actions among healthcare providers on how to manage cancer patients when faced with the threat of severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) infection. There has been a decrease in demand for nivolumab in some countries like the U.S., whereas many countries have seen an increase in sales with the rise in demand for the treatment and new cancer patients. With the rise in demand for the drug, FDA has provided approval to various drugs related to the immunotherapy nivolumab. For instance- · For the Bristol-Myers Squibb Company, the U.S. revenues of nivolumab decreased to 9% in 2020 due to lower demand caused by declining second-line eligibility across tumor indications and lower demand from COVID-19 (primarily lower new patient starts and patient visits). The U.S. has seen a decrease in sales in the first quarter of 2020. · However, the international revenues for nivolumab were increased up to 7% in 2020 due to higher demand as a result of additional indication launches in some countries with rising cancer patients globally. · In May 2021 -- Bristol-Myers Squibb Company has today announced that the U.S. Food and Drug Administration (FDA) had approved their Opdivo (nivolumab, injection for intravenous use) for the adjuvant treatment of completely resected esophageal or gastroesophageal junction (GEJ) cancer. · Similarly, FDA has approved Opdivo (nivolumab) for treating different types of cancer in many countries via various market players due to the rise in demand for this drug. IMPACT ON SUPPLY CHAIN The pandemic and COVID-19 have affected every business activity in which the supply chain was affected the most. Because of the pertinacious COVID-19 lockdown, sanctions have been forced by administrations of different nations. These limitations and boundaries across the nation’s borders prompted a diminishing stockpile because of restricted materials and labor force and the halting of the assembly line. The COVID-19 pandemic has transformed many organizations’ business environments; supply availability has been hampered by a number of issues, including export and travel restrictions by some producing countries, and the lockdown has forced suppliers to (temporarily) shut down. The supply of nivolumab medication has a slight decrease in sales during the first quarter of 2020, partly due to negative factors mentioned above in connection with the COVID-19 pandemic, which particularly didn’t affect the overall yearly revenue. The supply chain and demand were positively affected by the COVID 19. The sales and supply of the drugs have been increased with the rise in demand for the drugs and diagnosis. Many major manufacturing companies have launched their drugs in different countries to fulfill the demand, and the government has provided approval for the sales of the drug nivolumab. For instance- Despite the pandemic, many market player of nivolumab has increased their sales globally. This is due to the ongoing increase in the patient population and rising awareness regarding their health. · The sales of ONO pharmaceuticals have been increased in the year 2020 as compared to 2019, which is 2656.05 USD Million in 2019 and 2809.23 USD million. · Similarly, sales of the drug Opdivo (Nivolumab) from the manufacturing company Bristol Myers Squibb Company have been increased globally (except the U.S.) from USD 2,860 million in 2019 to USD 3,047 million in 2020. This increase in sales in both of the major market players is due to the increase in cancer patients and the use of drugs in all areas of cancer. There is an increase in the sales of this nivolumab with the rise in prevalence of disease and early diagnosis & treatment. STRATEGIC DECISIONS BY MANUFACTURERS To deal with the COVID-19 outbreak challenges and increasing demand for the drugs, many market players are creating new strategies such as new product development, telemedicine, and a different program to support patients and to raise their sales. It is predicted that these strategies are anticipated to escalate up the company revenue and its growth in the forecasted period. The government has provided drug FDA approvals of nivolumab for the treatment of cancer. For instance, · In May 2020, Bristol Myers Company announced that Opdivo (nivolumab) 3 mg/kg plus Yervoy (ipilimumab) 1 mg/kg (injections for intravenous use) was approved by the U.S. Food and Drug Administration (FDA) for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC). · There are several ongoing potentially registrational studies that have been conducted by different manufacturing companies for Opdivo for the treatment of different tumor types and disease areas, in combination with various anti-cancer agents · Also, there are various ongoing clinical trials conducting on nivolumab with the combination of various anti-cancer agents and others to treat various types of cancer to decrease the demand for cancer treatment and to provide patients with more advanced drugs. For instance · In Japan, South Korea, and Taiwan, ONO pharmaceuticals are co-developing this drug nivolumab with the Bristol Myers Company CONCLUSION As the pandemic of COVID-19 resulted in several restrictions throughout the borders, still, manufacturers and market players were able to manage their sales and revenue of oncology and drug nivolumab. Various manufacturers allowed their workers to work in a clean and safe environment so as to boost up the production at various manufacturing facilities across several regions of the world, thus, helping them to maintain a continuous supply chain with the increasing demand. Market players have come up with better strategies which have also created a positive impact on the growth of the nivolumab market globally.
How COVID-19 Impacted on Veterinary Vaccines in Healthcare Industry ?
COVID-19 Impact on Veterinary Vaccines in Healthcare Industry The animal health sector has witnessed significant developments over the past couple of years due to technological developments and efforts in Research and developments in veterinary sciences. One of the essential developments is antigen location using multiple bioinformatics methods and has been effectively used to immunize against various veterinary illnesses. Vaccines are a helpful to use way to protect animals against a variety of diseases. Vaccinology has produced several potent vaccinations that have significantly decreased the burden of certain severe illnesses in companion animals and cattle. Most approved veterinary vaccinations are available in live attenuated, killed/inactivated microorganisms, cell membrane compounds, or toxoids. The recent COVID-19 has an adverse the veterinary vaccines market as many animal drugs and vaccines were approved for human use. Animals infected with the virus have been reported all around the world. The majority of these animals, including a small number of domestic cats and dogs, got infected after coming into contact with people who had COVID-19. SARS-CoV-2 may infect companion animals like cats and dogs, large cats in zoos or sanctuaries, gorillas in zoos, mink on farms, and a few other mammals, but all of the species that can be infected in not been researched. Hence, the veterinary vaccines market is expected to play a vital role amidst the COVID-19 pandemic. IMPACT ON DEMAND The novel COVID-19 outbreak has led to a considerable rise in the demand for the veterinary vaccine. Veterinary offices worldwide made significant adjustments to guarantee that animals and livestock receive necessary veterinary care and that new safety procedures are in place to safeguard animals and veterinarians. As COVID-19 spread rapidly across the world and healthcare infrastructure became overwhelmed with COVID-19 cases. Coronaviruses can infect various domestic animals, including dogs, cats, cattle, pigs, and poultry. Routine vaccination can prevent many of these diseases. Vaccines against the canine coronavirus were in demand to protect puppies, although the illness is mild and self-limiting. In response to the surge in demand for veterinary vaccines, many veterinary producing companies were directed for the human COVID 19 vaccine, which impacted the production of veterinary vaccines. FOR INSTANCE- · In May 2021, Amid a shortage of COVID-19 vaccines as the country faces the second wave of infections, Bengaluru-based Institute of Animal Health and Veterinary Biologicals (IAH&VB) has offered to provide its state-of-the-art vaccine production facility to produce the vaccines IMPACT ON PRICE The veterinary services and vaccines prices were impacted due to COVID-19 up to some extent. Factors responsible for it were access to farming inputs, such as animal feed, livestock movements for pasture and water, animal equipment vaccinations, and other critical production inputs. Appeals to stay at home and social distance have had an impact on the pricing of veterinary vaccines. There been a whirlwind past months due to the emergence of COVID-19. The sale of some companies experienced a downfall while others managed to stay afloat. FOR INSTANCE, Common illness transmitted between species includes swine flu (H1N1), anthrax, and West Nile virus, to name a few. With more than 94.7 million cattle in the U.S. as of 2019 and more than 74.6 million pigs, the risk of zoonotic diseases transmitting to humans is a risk. It had an increase in prices for the veterinary vaccines IMPACT ON SUPPLY CHAIN The government throughout the globe imposed total lockdown, which led to supply chain disruptions. Consequently, the supply chain came to a standstill due to the closure of borders. Even though the demand for these devices was high, the availability was affected due to disruptions in the supply chain, trade, and travel restrictions. Supply of raw material was also affected, due to which the production was restricted. Veterinary services, such as routine vaccinations and testing and diagnostic instruments, were short supply for many farmers. As a result, animal illness control has emerged a new task that coincides with animal welfare concerns. However, the impact of COVID-19 on animal healthcare operations is not limited to the farm level; there are also national and international limitations. Due to funding constraints, several national and international animal health care programs/projects have been postponed or discontinued, limiting the success of disease elimination due to COVID 19. Several companies working on veterinary vaccines have indicated that the reductions in fluidity and foreign exchange were other significant factors affecting the sustainability of the livestock supply chain, specifically in developing countries during the pandemic. FOR INSTANCE: · The E.U. Executive Steering Group on Shortages of Medicines Caused by Major Events has provided strategic leadership for urgent and coordinated action to prevent and mitigate supply disruption during the pandemic The European Commission chairs the steering group. It consists of representatives of EMA, the European Commission, Heads of Medicines Agencies (HMA) and the Coordination groups for Mutual Recognition and Decentralised Procedures for human and veterinary medicines (CMDh and CMDv), as well as risk communication specialists PERSPECTIVE AND INITIATIVES: As the reality of COVID-19 dawned upon the world, the manufacturers and production units of companies involved in veterinary vaccines manufacturing industries and governments had various perspective and initiatives taken regarding the market. FOR INSTANCE: · In July 2021, Minister of Agriculture and Land Reclamation El Sayed El Quseir discussed investment in the production of veterinary vaccines and serums with Dr. Chris Nelson, Management Advisor of the Egyptian-American Middle East for Veterinary Vaccines (MEVAC) pharmaceutical company and President and CEO of the U.S. Kemin Industries · In July 2021, Zoetis donated more than 11,000 doses of its experimental COVID-19 vaccine to help protect the health and well-being of more than 100 mammalian species living in nearly 70 zoos, as well as more than a dozen conservatories, sanctuaries, academic institutions, and government organizations located in 27 states in new jersey CONCLUSION COVID-19 has impacted each sector with no exception. The veterinary vaccines market has been affected the same. With rising awareness around of vaccination against cattle diseases and improved health facilities for animal husbandry, there is a rise in demand for veterinary vaccines up to some extent. However, in the crisis call veterinary vaccine manufacturers, key players, government bodies, and healthcare organizations are working closely with healthcare professionals, customers, and patients for the betterment of animal health. Moreover, animal drugs and vaccines were approved for human use. Animals infected with the virus have been reported all around the world. Also, veterinary vaccine manufacturing facilities were used for production of human COVID vaccines around the worked. This is expected to impact the market for veterinary vaccines up to some extent.
Significant COVID-19 Impact on Non-Small Cell Lung Cancer Diagnostics in Healthcare Industry
COVID-19 Impact on Non-Small Cell Lung Cancer Diagnostics in Healthcare Industry The novel coronavirus has profoundly impacted all fields, including healthcare, medical device services, automotive, pharmaceutical and many others. This pandemic has led to shutdowns of mass production and disruptions in the supply chain that have impacted the economies of virtually every nation in the world. The pandemic also affected the non-small cell lung cancer diagnostic industry. The patient's fear of contracting the virus compels patients to stay home instead of undergoing diagnosis and treatment. During the COVID-19 pandemic, countries worldwide witnessed a large number of patients suffering from COVID-19 and post COVID-19 complications such as cardiovascular disease, diabetes and kidney problems. As the COVID-19 cases were rising, the healthcare system had shifted its focus in curbing the disease, thereby delaying diagnosis and treatment of other chronic conditions as cancer. Thus, a negative impact is expected on the non-small cell lung cancer diagnostics market due to the pandemic scenario As a result, the hospitals and clinics were filled up with COVID-19 patients and less preference was given to non-small cell lung cancer patients. Moreover, limited access to clinics, social distancing, the lockdown of the population, which results in a slow-down in patient flow and referrals, has also impacted the market growth. However, with the cases decreasing in number and increase in vaccination against COVID-19 across the globe, the market for non-small cell lung cancer diagnostics market may get a boost due to some relaxation in COVID-19 cases, which will result in increased demand for non-small cell lung cancer diagnosis with patients coming forward to clinics and hospitals for treatment. IMPACT ON DEMAND Various screening, diagnostic and surgical procedures were restricted and at hospitals and cancer treatment centers, which resulted in disruptions in the non-small cell lung cancer diagnostics market. However, even during the pandemic, the lung cancer cases were subsequent, which is expected to increase the demand for non-small cell lung cancer diagnostics market. For instance, · According to World Health Organization (WHO), in 2020, lung cancer accounted for 2,206 771 deaths among both sexes. The lung cancer statistics include both small cell lung cancer and non-small cell lung cancer. About 13% of all lung cancers are small cell lung cancer and 84% are non-small cell lung cancer. This proves an increase in the number of non-small cell lung cancer patients even during the COVID-19 pandemic. Moreover, according to the American Cancer Society, Inc., lung cancer patients are likely to get infected with coronavirus because of the changes in their immune system that control their body's defense systems. For instance, · According to a study published in PubMed, patients with lung cancer are at an increased risk of becoming infected with the virus and experience higher morbidity and mortality than the general population Thus, having cancer such as non-small cell lung cancer may also increase the risk of severe illness from COVID-19 as the cancer therapy treatment reduce the immune system of the body. . This has increased the demand for non-small cell lung cancer diagnostic tools, especially in cancer-dedicated hospitals and surgical centres, where all the patients of non-small cell lung cancer-related problems are treated. Thus, with the increased lung cancer cases, the demand for non-small cell lung cancer diagnostic will increase in the coming years. IMPACT ON SUPPLY CHAIN The supply chain was widely affected by the COVID-19 pandemic as acute restrictions and lockdowns produced many urgent situations in the early days of the pandemic, which needed immediate attention. The supply chain disruption has transformed many organizations' business environments, including the supply chain of non-small cell lung cancer diagnostics market. The supply chain disruption impacted the Asia-Pacific region initially, especially the demand from China due to challenges from restricted movement and quarantine period. For instance, · According to the FDA, 63 manufacturers representing 72 facilities in China that produce essential medical devices face obstacles in manufacturing medical devices and their supply, owing to citing workforce challenges and the necessary quarantine of workers. Moreover, closing borders of various countries is anticipated to diminish the supply chain business environment, as it may hamper export of the medical supplies To minimize supply chain crises, the FDA has been firmly monitoring the supply chain with the assumption that the COVID-19 outbreak may adversely impact the supply chain of medical products, including shortages of critical medical products in the U.S. or potential disruptions in supply chains. Many organizations and countries are looking forward to improving and diversified supply chain models in all aspects to manage such a crucial situation. A diversified supply chain model anticipated minimizing the export of medical products as well as increase end-to-end visibility. For instance, · The Brazilian government published a resolution eliminating import taxes on 141 medical products and hospital equipment · The European Commission made a decision for helping Member States affected by the pandemic to suspend customs duties and VAT on medical devices temporarily · Federal indirect tax body the Goods and Services Tax (GST) Council of India has decided to cut taxes on medical supplies IMPACT ON PRICE The coronavirus disease (COVID-19) pandemic does not significantly impact the global non-small cell lung cancer diagnostics market. But it is estimated that if COVID-19 continues to spread for a prolonged period, then the demand for non-small cell lung cancer diagnostic equipment and devices will highly upsurge for top importer countries. For therapies and the diagnostic United States solicit the huge number of medical devices, followed by China and Japan. For instance, · According to the General Administration of Customs (GAC), China's exports of medical machinery and devices increased 40.5 percent in 2020 compared to the previous year, reaching USD 18.138 billion · According to the World Trade Organisation, the U.S. imports and exports of medical goods increased by 16 %, reaching USD 1,139.00 billion in value Henceforth for diagnosis, dependency of these countries highly increases on other exporters and many countries solely depend on China and the U.S. for the non-small cell lung cancer diagnostic equipment. Consequently, this may lead to a rise in the overall non-small cell lung cancer diagnostic cost. This increase in the price of the non-small cell lung cancer diagnostic may hamper the market growth if it continues to be the same. Additionally, if the lockdown continues to stretch for a long period, then import of non-small cell lung cancer diagnostics market is estimated to get more restricted, which may further lead to a rise in the price of the these devices CONCLUSION It is estimated that the COVID-19 pandemic outbreak has significantly impacted the growth of non-small cell lung cancer diagnostics market as the rising cases of COVID-19 worldwide the healthcare system had shifted its focus in curbing the disease, thereby resulting in the delay of diagnosis and treatment of non-small cell lung cancer. Thus, a negative impact is expected on the non-small cell lung cancer diagnostics market due to the pandemic scenario. However, with the increase in lung cancer patients worldwide, the demand for non-small cell lung cancer diagnostics will increase in the coming years. Moreover, poor lifestyle, smoking, alcohol consumption, lack of physical activity and other factors will contribute to the incidence of chronic disease such as lung cancer, including non-small cell lung, which is anticipated to increase the global non-small cell lung cancer diagnostics market in the coming years.